Here, we systemically profiled complement activation in immunotherapy-naive patients with neuronal cell surface-specific Abs, patients with GAD-Ab+ encephalitis, patients with relapsing–remitting multiple sclerosis (RMS) and healthy subjects (HD) (Supplementary Table 1). This evidence concerns the gene GAD1 and encephalitis.